Lingo is the second example in the glucose cell of DEPLOY's biometric cohort and anchors its adaptive-algorithmic end: the documented contrast to Stelo's generative AI, the within-cell AI-substance gradient made concrete.
✔
It is FDA 510(k)-cleared (K233655, May 29, 2024), built on Abbott's proven FreeStyle Libre sensor platform, worn up to 14 days, for non-diabetic and wellness consumers.
The price above is verified: about $54 for a 2-week single-biosensor starter plan, with recurring biweekly and monthly multi-sensor tiers. It is a recurring biosensor subscription, not a one-time device.
Availability
Shipping now
Lingo is shipping and consumer-available over the counter for non-diabetic and wellness consumers. From Abbott (NYSE: ABT), it is built on Abbott's FreeStyle Libre sensor platform.
Real-world status
Abbott's Lingo is an over-the-counter continuous glucose monitor for non-diabetic and wellness consumers, built on the FreeStyle Libre sensor platform (FDA 510(k) K233655, May 29, 2024; Class II integrated CGM), worn up to 14 days on the upper arm. It is the adaptive-algorithmic end of the glucose cell, the documented contrast to Stelo's generative AI: the 'Lingo Count' daily glucose-spike metric with adaptive targets, food and activity logging, and rule-based recommendations are adaptive-algorithmic, not generative. 'Lingo Live' is free roughly 30-minute sessions with human Abbott nutritionists, not an AI coach, a distinction DEPLOY surfaces prominently. The cleared indication is adults 18+ not on insulin, explicitly not for diagnosis of any disease including diabetes.
⚠
An honest-AI distinction: Lingo's intelligence is adaptive-algorithmic (Lingo Count, adaptive targets, rule-based recommendations), NOT generative like Stelo. And 'Lingo Live' coaching is free sessions with human Abbott nutritionists, not an AI coach. The cleared indication is adults 18+ not on insulin, not for diagnosis of any disease including diabetes.
💡
At the corporate level Abbott's FreeStyle Libre is the CGM counterpart to Dexcom; Lingo is Abbott's OTC wellness expression of that platform, the Libre-based answer to Dexcom's Stelo.
OTC glucose monitors: Lingo vs Stelo
Abbott Lingo
Dexcom Stelo
Price
~$54/2wk
🟢verified
~$89/2wk
🟢verified
FDA
510(k) K233655 (May 2024)
🟢verified
De Novo (first OTC CGM, Mar 2024)
🟢verified
AI substance
Adaptive-algorithmic
🟢verified
Generative (Vertex/Gemini)
🟢verified
Coaching
Human nutritionists (Lingo Live)
🟢verified
AI recommendations
🟢verified
Platform
FreeStyle Libre
🟢verified
Dexcom (OTC line)
🟢verified
Sources: DEPLOY registry, Abbott / FDA, DexCom / FDA
Frequently Asked Questions
How much is Abbott Lingo?
About $54 for a 2-week single-biosensor starter plan🟢verified, with recurring biweekly and monthly multi-sensor tiers. A recurring subscription, not a one-time device.
Does Lingo use AI?
Adaptive-algorithmic, not generative🟢verified: Lingo Count with adaptive targets and rule-based recommendations. The 'Lingo Live' coaching is human Abbott nutritionists, not an AI coach.
Do you need a prescription for Lingo?
No🟢verified. It is an OTC CGM (FDA 510(k) K233655, May 2024) for adults 18+ not on insulin, not for diagnosis of any disease including diabetes.
Is Lingo the same as FreeStyle Libre?
It is built on the FreeStyle Libre sensor platform🟢verified, as Abbott's OTC wellness product for non-diabetic consumers; Libre is the broader Abbott CGM line.
How does Lingo compare to Dexcom Stelo?
Both are OTC CGMs for adults 18+ not on insulin🟢verified; Lingo's AI is adaptive-algorithmic with human coaching, while Stelo's is generative (Vertex/Gemini). Lingo is cheaper (~$54 vs ~$89/2 weeks).
Pricing and availability are tagged verified or claimed against primary sources. Manufacturer targets are reported as targets, not prices you can pay today.